# Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

> **NCT00435292** · NA · COMPLETED · sponsor: **Primus Pharmaceuticals** · enrollment: 350 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** Naproxen
- **DIETARY_SUPPLEMENT:** flavocoxid 250 mg
- **DIETARY_SUPPLEMENT:** flavocoxid 500 mg

## Key facts

- **NCT ID:** NCT00435292
- **Lead sponsor:** Primus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435292, "Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00435292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*